Drug Profile
Research programme: plasmin inhibitors - Omeros
Alternative Names: OMS 616Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator University of California at Los Angeles
- Developer Omeros Corporation
- Class Proteins
- Mechanism of Action Blood coagulation factor modulators; Plasmin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haemorrhage